The University of Texas System

Shanghai Okway Intelligent Equipment Co., Ltd

Shanghai Kelai Mechatronics Engineering Corp.

Wentao Yang

Mien-Chie Hung

Dihua Yu

Xiaoyan Zhou

Jun Yang

Ping Li

Jun Yao

Raphael E Pollock

Nina T Nguyen

Christopher L Neal

Junjie Shen

Jianliang Su

Shili Tan

Zongyang Liu

Yongyi He

Provided is a logistics palletizing system. The logistics palletizing system includes a palletizer including a walking device, a telescopic platform device, a feeding device, a multi-stage lifting device and a feed diverting device, where the telescopic platform device is mounted above the walking device, the multi-stage lifting device and the feed diverting device are each mounted on the telescopic platform device, and the telescopic platform device is configured to drive the multi-stage lifting device and the feed diverting device to move in a preset direction relative to the walking device; and the feeding device is mounted on the multi-stage lifting device, the multi-stage lifting device is configured to drive the feeding device up and down, the feed diverting device is configured to convey materials to the feeding device, and the feeding device is configured to palletize the materials.

Logistics palletizing system

Methods of determining prognosis in a subject with a hyperproliferative disease, including determining expression and/or function of 14-3-3 zeta in the subject, are disclosed. Also disclosed are methods of making a pharmaceutical agent that modulates apoptosis, including the steps of obtaining one or more candidate, testing the one or more candidate substances to determine their ability to modulate the expression and/or function of 14-3-3 zeta, selecting a candidate substance determined to modulate the expression and/or function of 14-3-3 zeta, and making a pharmaceutical composition that includes the selected candidate substance. In addition, methods of treating a subject with a hyperproliferative disease, including making a pharmaceutical agent by the methods set forth herein, and administering the pharmaceutical agent to a subject, are disclosed. The hyperproliferative disease can be cancer, such as breast cancer.

14-3-3 Zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer type

14-3-3 zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer types

Growing community of inventors

Shanghai, China

Wentao Yang